Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity ...

Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions. Neither ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...

This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.